Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Compare

7,306 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TEVA Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Teva

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TEVA Stock 12 Month Forecast

Average Price Target

$23.86

▲(46.29%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Teva Pharmaceutical in the last 3 months. The average price target is $23.86 with a high forecast of $30.00 and a low forecast of $20.00. The average price target represents a 46.29% change from the last price of $16.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","31":"$31","18.25":"$18.25","22.5":"$22.5","26.75":"$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.25,22.5,26.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.64,17.66769230769231,18.695384615384615,19.723076923076924,20.75076923076923,21.77846153846154,22.806153846153848,23.833846153846153,24.861538461538462,25.88923076923077,26.916923076923077,27.944615384615386,28.972307692307695,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.64,17.195384615384615,17.75076923076923,18.306153846153848,18.861538461538462,19.416923076923077,19.97230769230769,20.527692307692305,21.083076923076923,21.638461538461538,22.193846153846152,22.74923076923077,23.30461538461538,{"y":23.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.64,16.89846153846154,17.15692307692308,17.415384615384617,17.673846153846153,17.932307692307692,18.19076923076923,18.44923076923077,18.70769230769231,18.966153846153848,19.224615384615383,19.483076923076922,19.74153846153846,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$23.86

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$17

Hold

4.23%

Upside

Reiterated

07/08/25

Teva's stock score is primarily impacted by financial challenges, including high debt and inconsistent profitability. While strategic initiatives and positive earnings outlook offer hope, valuation concerns remain a significant hurdle.

Matthew DellatorreGoldman Sachs

Goldman Sachs

$24

Buy

47.15%

Upside

Reiterated

07/15/25

Goldman Sachs Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

Jason GerberryBank of America Securities

Bank of America Securities

$22

Buy

34.89%

Upside

Reiterated

07/14/25

Teva Pharmaceutical's Austedo Poised for Growth: Analyst Recommends Buy Rating

Chris SchottJ.P. Morgan

J.P. Morgan

$23

Buy

41.02%

Upside

Reiterated

07/09/25

Teva Pharmaceutical's Promising Growth Prospects and Strategic Initiatives Drive Buy Rating

Ashwani VermaUBS

UBS

$24→$23

Buy

41.02%

Upside

Reiterated

06/27/25

Teva price target lowered to $23 from $24 at UBSTeva price target lowered to $23 from $24 at UBS

David AmsellemPiper Sandler

Piper Sandler

$30

Buy

83.94%

Upside

Reiterated

05/30/25

Piper Sandler Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Les SulewskiTruist Financial

Truist Financial

$25

Buy

53.28%

Upside

Initiated

05/28/25

Teva initiated with a Buy at TruistTeva initiated with a Buy at Truist

Rajesh KumarHSBC

HSBC

$24→$20

Buy

22.62%

Upside

Reiterated

04/28/25

Teva price target lowered to $20 from $24 at HSBCTeva price target lowered to $20 from $24 at HSBC

Glen SantangeloJefferies

Jefferies

$23

Buy

41.02%

Upside

Reiterated

03/31/25

Positive Outlook for Teva Pharmaceuticals: Buy Rating Reiterated Amid Growth Initiatives and Improved Transparency

Balaji PrasadBarclays

Barclays

$26

Buy

59.41%

Upside

Reiterated

02/25/25

Barclays Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

01/31/25

Evercore ISI Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Jasper HellwegArgus Research

Argus Research

$20

Buy

22.62%

Upside

Reiterated

01/30/25

Teva Pharmaceutical (TEVA) Gets a Buy from Argus Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$17

Hold

4.23%

Upside

Reiterated

07/08/25

Matthew DellatorreGoldman Sachs

Goldman Sachs

$24

Buy

47.15%

Upside

Reiterated

07/15/25

Goldman Sachs Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

Jason GerberryBank of America Securities

Bank of America Securities

$22

Buy

34.89%

Upside

Reiterated

07/14/25

Teva Pharmaceutical's Austedo Poised for Growth: Analyst Recommends Buy Rating

Chris SchottJ.P. Morgan

J.P. Morgan

$23

Buy

41.02%

Upside

Reiterated

07/09/25

Teva Pharmaceutical's Promising Growth Prospects and Strategic Initiatives Drive Buy Rating

Ashwani VermaUBS

UBS

$24→$23

Buy

41.02%

Upside

Reiterated

06/27/25

Teva price target lowered to $23 from $24 at UBSTeva price target lowered to $23 from $24 at UBS

David AmsellemPiper Sandler

Piper Sandler

$30

Buy

83.94%

Upside

Reiterated

05/30/25

Piper Sandler Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Les SulewskiTruist Financial

Truist Financial

$25

Buy

53.28%

Upside

Initiated

05/28/25

Teva initiated with a Buy at TruistTeva initiated with a Buy at Truist

Rajesh KumarHSBC

HSBC

$24→$20

Buy

22.62%

Upside

Reiterated

04/28/25

Teva price target lowered to $20 from $24 at HSBCTeva price target lowered to $20 from $24 at HSBC

Glen SantangeloJefferies

Jefferies

$23

Buy

41.02%

Upside

Reiterated

03/31/25

Positive Outlook for Teva Pharmaceuticals: Buy Rating Reiterated Amid Growth Initiatives and Improved Transparency

Balaji PrasadBarclays

Barclays

$26

Buy

59.41%

Upside

Reiterated

02/25/25

Barclays Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Umer RaffatEvercore ISI

Evercore ISI

―

Buy

―

Reiterated

01/31/25

Evercore ISI Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Jasper HellwegArgus Research

Argus Research

$20

Buy

22.62%

Upside

Reiterated

01/30/25

Teva Pharmaceutical (TEVA) Gets a Buy from Argus Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Teva Pharmaceutical

1 Month

xxx

Success Rate

8/15 ratings generated profit

Average Return

-0.59%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -0.59% per trade.

3 Months

xxx

Success Rate

14/25 ratings generated profit

Average Return

+2.48%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +2.48% per trade.

1 Year

Balaji PrasadBarclays

Success Rate

12/25 ratings generated profit

Average Return

+17.16%

reiterated a buy rating 5 months ago

Copying Balaji Prasad's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of +17.16% per trade.

2 Years

xxx

Success Rate

12/25 ratings generated profit

Average Return

+19.92%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 48.00% of your transactions generating a profit, with an average return of +19.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TEVA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TEVA has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. TEVA average Analyst price target in the past 3 months is 23.86.

Each month's total comprises the sum of three months' worth of ratings.

TEVA Financial Forecast

TEVA Earnings Forecast

Next quarter’s earnings estimate for TEVA is $0.62 with a range of $0.59 to $0.64. The previous quarter’s EPS was $0.52. TEVA beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.18% of the time in the same period. In the last calendar year TEVA has Outperformed its overall industry.

TEVA Sales Forecast

Next quarter’s sales forecast for TEVA is $4.28B with a range of $4.20B to $4.32B. The previous quarter’s sales results were $3.86B. TEVA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year TEVA has Outperformed its overall industry.

TEVA Stock Forecast FAQ

What is TEVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Teva Pharmaceutical’s 12-month average price target is 23.86.

What is TEVA’s upside potential, based on the analysts’ average price target?

Teva Pharmaceutical has 46.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TEVA a Buy, Sell or Hold?

Teva Pharmaceutical has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Teva Pharmaceutical’s price target?

The average price target for Teva Pharmaceutical is 23.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $20.00. The average price target represents 46.29% Increase from the current price of $16.31.

What do analysts say about Teva Pharmaceutical?

Teva Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of TEVA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

TEVA Analyst Ratings

TEVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Teva Pharmaceutical

TEVA Analyst Recommendation Trends

TEVA Financial Forecast

TEVA Earnings Forecast

TEVA Sales Forecast

TEVA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts